NovaBridge Biosciences (Nasdaq: NBP), a biotechnology platform company, announced new data from the expanded Phase 1 dosing study of ragistomig, a 4-1BB X PD-L1 bispecific antibody. The data will be presented at the ESMO-IO 2025 by ABL Bio. Poster (Abstract #688) to be presented by Gerald Falchook, MD, Director of Sarah Cannon Research Institute at HealthONE Denver, on December 10th at 5:30 PM GMT.